Literature DB >> 18601691

The tissue-specific processing of pro-opiomelanocortin.

A B Bicknell1.   

Abstract

It is just over 30 years since the definitive identification of the adrenocorticotrophin (ACTH) precursor, pro-opiomelanocotin (POMC). Although first characterised in the anterior and intermediate lobes of the pituitary, POMC is also expressed in a number of both central and peripheral tissues including the skin, central nervous tissue and placenta. Following synthesis, POMC undergoes extensive post-translational processing producing not only ACTH, but also a number of other biologically active peptides. The extent and pattern of this processing is tissue-specific, the end result being the tissue dependent production of different combinations of peptides from the same precursor. These peptides have a diverse range of biological roles ranging from pigmentation to adrenal function to the regulation of feeding. This level of complexity has resulted in POMC becoming the archetypal model for prohormone processing, illustrating how a single protein combined with post-translational modification can have a diverse number of roles.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18601691     DOI: 10.1111/j.1365-2826.2008.01709.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  40 in total

1.  beta-Endorphin expression in the mouse retina.

Authors:  Shannon K Gallagher; Paul Witkovsky; Michel J Roux; Malcolm J Low; Veronica Otero-Corchon; Shane T Hentges; Jozsef Vigh
Journal:  J Comp Neurol       Date:  2010-08-01       Impact factor: 3.215

2.  cDNA cloning, pituitary location, and extra-pituitary expression of pro-opiomelanocortin gene in rare minnow (Gobiocypris rarus).

Authors:  Xiaohong Liu; Biwen Xie; Yaoguang Zhang; Deshou Wang; Zhijian Wang
Journal:  Fish Physiol Biochem       Date:  2010-09-29       Impact factor: 2.794

3.  Functional melanocortin-2 receptors are expressed by mouse aorta-derived mesenchymal progenitor cells.

Authors:  Jodi F Evans; Anne Fernando; Louis Ragolia
Journal:  Mol Cell Endocrinol       Date:  2012-01-27       Impact factor: 4.102

4.  Proton Sensitivity of Corticotropin-Releasing Hormone Receptor 1 Signaling to Proopiomelanocortin in Male Mice.

Authors:  Hiraku Kameda; Masaaki Yamamoto; Yukiko Tone; Masahide Tone; Shlomo Melmed
Journal:  Endocrinology       Date:  2019-02-01       Impact factor: 4.736

5.  Type B pigmentary demarcation lines of pregnancy involving the anterior thighs and knees.

Authors:  Eujin Cho; Jong Ho Lim; Hei Sung Kim; Young Min Park; Jun Young Lee; Hyung Ok Kim
Journal:  Ann Dermatol       Date:  2012-07-25       Impact factor: 1.444

6.  Glycyl-glutamine (beta-endorphin(30-31)) inhibits morphine-induced dopamine efflux in the nucleus accumbens.

Authors:  Nesrin Filiz Basaran; R Levent Buyukuysal; William R Millington; Sinan Cavun
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-27       Impact factor: 3.000

7.  Intermediate lobe immunoreactivity in a patient with suspected lymphocytic hypophysitis.

Authors:  Casey Jo Anne Smith; Sophie Bensing; Vicki E Maltby; Mingdong Zhang; Rodney J Scott; Roger Smith; Olle Kämpe; Tomas Hökfelt; Patricia A Crock
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

Review 8.  MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation.

Authors:  Jose C García-Borrón; Zalfa Abdel-Malek; Celia Jiménez-Cervantes
Journal:  Pigment Cell Melanoma Res       Date:  2014-05-30       Impact factor: 4.693

9.  Posttranslational processing of human and mouse urocortin 2: characterization and bioactivity of gene products.

Authors:  Joan M Vaughan; Cynthia J Donaldson; Wolfgang H Fischer; Marilyn H Perrin; Jean E Rivier; Paul E Sawchenko; Wylie W Vale
Journal:  Endocrinology       Date:  2013-03-14       Impact factor: 4.736

Review 10.  Neurokinin B and pre-eclampsia: a decade of discovery.

Authors:  Nigel M Page
Journal:  Reprod Biol Endocrinol       Date:  2010-01-14       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.